Enzon Pharmaceuticals Statistics
Total Valuation
ENZN has a market cap or net worth of $12.62 million. The enterprise value is -$33.37 million.
| Market Cap | 12.62M |
| Enterprise Value | -33.37M |
Important Dates
The last earnings date was Monday, March 18, 2013, before market open.
| Earnings Date | Mar 18, 2013 |
| Ex-Dividend Date | n/a |
Share Statistics
ENZN has 74.21 million shares outstanding.
| Shares Outstanding | 74.21M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | +0.00% |
| Owned by Insiders (%) | 10.84% |
| Owned by Institutions (%) | 48.58% |
| Float | 30.11M |
Valuation Ratios
The trailing PE ratio is 56.67.
| PE Ratio | 56.67 |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 0.27 |
| P/FCF Ratio | 9.10 |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 89.19, with zero debt.
| Current Ratio | 89.19 |
| Quick Ratio | n/a |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is 3.23% and return on invested capital (ROIC) is -2.55%.
| Return on Equity (ROE) | 3.23% |
| Return on Assets (ROA) | 3.19% |
| Return on Capital (ROIC) | -2.55% |
| Revenue Per Employee | n/a |
| Profits Per Employee | n/a |
| Employee Count | n/a |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | -120,000 |
| Effective Tax Rate | -8.72% |
Stock Price Statistics
The stock price has decreased by -14.96% in the last 52 weeks. The beta is 0.49, so ENZN's price volatility has been lower than the market average.
| Beta (5Y) | 0.49 |
| 52-Week Price Change | -14.96% |
| 50-Day Moving Average | 0.13 |
| 200-Day Moving Average | 0.11 |
| Relative Strength Index (RSI) | 54.08 |
| Average Volume (20 Days) | 41,779 |
Short Selling Information
The latest short interest is 259,381, so 0.35% of the outstanding shares have been sold short.
| Short Interest | 259,381 |
| Short Previous Month | 298,381 |
| Short % of Shares Out | 0.35% |
| Short % of Float | 0.86% |
| Short Ratio (days to cover) | 1.71 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -1.09M |
| Pretax Income | 1.38M |
| Net Income | 1.50M |
| EBITDA | -1.09M |
| EBIT | n/a |
| Earnings Per Share (EPS) | $0.00 |
Balance Sheet
The company has $45.99 million in cash and no debt, giving a net cash position of $45.99 million or $0.62 per share.
| Cash & Cash Equivalents | 45.99M |
| Total Debt | n/a |
| Net Cash | 45.99M |
| Net Cash Per Share | $0.62 |
| Equity (Book Value) | 46.31M |
| Book Value Per Share | 0.62 |
| Working Capital | 45.95M |
Cash Flow
| Operating Cash Flow | 1.39M |
| Capital Expenditures | n/a |
| Free Cash Flow | 1.39M |
| FCF Per Share | $0.02 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
ENZN does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | 1 |
| Payout Ratio | n/a |
| Buyback Yield | n/a |
| Shareholder Yield | n/a |
| Earnings Yield | 11.86% |
| FCF Yield | 10.99% |
Analyst Forecast
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | Sep 29, 2017 |
| Split Type | n/a |
| Split Ratio | 1:1 |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 3 |